Objective: To study whether exposure to childhood emotional, sexual or physical abuse is associated with subsequent multiple sclerosis (MS) development.
Association of adverse childhood experiences with the development of multiple sclerosis
From the center
Encouraging results from our phase-I trial (NADPARK)
Can medicine weaken the human capacity to tolerate suffering?
Major funding for our Parkinson’s research from the Norwegian Health Authorities
The Parkinson’s research program led by Prof. Charalampos Tzoulis at the Neuro-SysMed Center has been strengthened by grants from the regional and national Norwegian Health Authorities, amounting to more than 3 million Euros.
The grants will fund clinical studies led by Prof. Tzoulis’ group, including NOPARK.
NOPARK is a phase II, double-blinded randomized clinical trial of NAD-replenishment therapy by oral nicotinamide riboside (NR) in Parkinson’s disease. The trial will determine whether NR has neuroprotective action and delays the motor and non-motor progression of Parkinson’s disease. A total of 400 persons with Parkinson’s disease who have had the diagnosis for up to 2 years will be recruited from all of Norway.
https://helse-bergen.no/kliniske-studier/parkinson-sykdom-behandling-med-nikotinamid-nopark-studien
Creativity & Innovation Leadership – Inspirational lectures and discussions with invited speakers Ole Dahlberg and Ingunn Johanne Ness.
Welcome to a CCBIO and Neuro-SysMed Special Seminar on Creativity & Innovation Leadership. Inspirational lectures and discussions with invited speakers Ole Dahlberg and Ingunn Johanne Ness.
Fiona Dick defending her PhD on studies of gene expression in the Parkinson’s disease brain
Three courses are available in the research school during the fall of 2021
Webinar about patient and public participation in clinical trials
